Myeloid Therapeutics Rebrands as Create Medicines, Expands Focus Beyond Myeloid Cells

Myeloid Therapeutics, a biotech company founded in 2021, has undergone a significant transformation, rebranding itself as Create Medicines to reflect its expanded pipeline and research focus. The company, which initially centered on myeloid cell-based therapies, has broadened its scope to include T cells and NK cells, marking a strategic shift in its approach to immunotherapy.

Expanded Pipeline and Clinical Progress

Create Medicines has made substantial progress since its inception, with two in vivo mRNA CAR candidates, MT-302 and MT-303, currently in phase 1 trials. These therapies are designed to reprogram immune cells to target TROP2 and GPC3, receptors overexpressed in certain cancers. The company's clinical work has involved more than 40 patients, demonstrating the ability to tolerably and repeatedly program immune cells inside the body.

Building on this foundation, Create Medicines is now advancing MT-304, a HER2 multi-immune CAR for breast cancer that engages both NK and myeloid cells. This marks the company's first venture beyond myeloid cells, signaling a new direction in its research and development efforts.

Innovative Approaches in Oncology and Immunology

In addition to its clinical-stage programs, Create Medicines is pushing the boundaries of immunotherapy with novel preclinical candidates. The company announced plans to develop the first-ever RNA retrotransposon-based in vivo CAR-T for B-cell depletion, targeting both oncology and autoimmune indications. This innovative approach could potentially revolutionize the field of cell therapy by enabling in vivo programming of T cells.

CEO Daniel Getts, Ph.D., emphasized the company's evolving capabilities, stating, "We are now extending those capabilities to program multiple immune lineages for deeper, more durable responses, starting with MT-304, our HER2 multi-immune CAR in breast cancer."

Financial Backing and Future Outlook

Despite a reported restructuring earlier this year that narrowed the company's focus on its clinical candidates, Create Medicines maintains strong investor support. The biotech raised $73 million in 2023 from a syndicate including Hatteras Investment Partners, Arch Venture Partners, Newpath Partners, and 8VC. This financial backing underscores investor confidence in the company's expanded vision and innovative pipeline.

As Create Medicines moves forward with its rebranded identity, the company is poised to leverage its multi-immune programming platform across a broader range of therapeutic applications, potentially opening new avenues for treating cancer and autoimmune diseases.